Anthem Biosciences (ANTHEM) investor relations material

Executive summary

• Q1 FY 2027 revenue was INR 418 crores, with CRDMO contributing 81.5% and Specialty Ingredients 18.5%.

• Q1FY27 results were impacted by timing shifts in deliveries, with stronger performance expected in the latter half of the year.

• EBITDA reached INR 176 crores (39.6% margin), PAT was INR 120 crores (27.1% margin).

• Net cash position as of June 30, 2026, stood at INR 1,720 crores (17,197 Mn).

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved and reviewed by the Board and Audit Committee on July 21, 2026.

Financial highlights

• Q1 FY27 consolidated revenue was 4,182 Mn, down 22.6% year-over-year and 31.5% sequentially, mainly due to deferred deliveries.

• EBITDA margin improved to 39.6%, up 153 bps year-over-year.

• PAT margin increased to 27.1% year-over-year.

• ESOP cost for FY 2027 is INR 9 crores, down from INR 16 crores in FY 2026.

• Standalone and consolidated net profit for Q1 FY27 was Rs 1,020.09 Mn and Rs 1,199.41 Mn, respectively.

Outlook and guidance

• Growth prospects for FY 2027 remain intact, with expectations to match historical double-digit growth.

• 60% of the annual order book is already secured, providing high visibility for the year.

• Higher concentration of scheduled deliveries anticipated in the second half of FY27, expected to drive revenue momentum.

• Margins expected to remain strong, supported by cost efficiencies and innovation.

• Q1 is expected to be the softest quarter; sequential growth anticipated from Q2 onwards.